| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.37▲ | 3.45▼ | 3.48▼ | 3.62▼ | 4.36▼ |
| MA10 | 3.43▼ | 3.45▼ | 3.51▼ | 3.60▼ | 6.10▼ |
| MA20 | 3.43▼ | 3.58▼ | 3.61▼ | 4.50▼ | 3.49▼ |
| MA50 | 3.59▼ | 3.99▼ | 4.16▼ | 6.27▼ | 2.37▲ |
| MA100 | 4.27▼ | 5.52▼ | 6.70▼ | 3.58▼ | N/A |
| MA200 | 5.89▼ | 4.83▼ | 3.88▼ | 2.49▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.026▲ | 0.039▲ | -0.045▼ | -0.088▼ |
| RSI | 41.020▼ | 35.344▼ | 33.657▼ | 32.914▼ | 47.476▼ |
| STOCH | 23.810 | 41.154 | 38.496 | 30.382 | 15.381▼ |
| WILL %R | -65.385 | -82.353▼ | -83.784▼ | -97.556▼ | -87.449▼ |
| CCI | -73.789 | -113.235▼ | -102.352▼ | -71.382 | -34.813 |
|
Tuesday, September 30, 2025 05:56 AM
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence ...
|
|
Tuesday, September 30, 2025 05:50 AM
Silexion Therapeutics (SLXN) announced that SIL204 has demonstrated activity against eleven human cell lines originating from ...
|
|
Friday, September 26, 2025 11:30 PM
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital MarketGRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 3.68 | 3.68 | 3.27 | 3.38 | 5,565,670 |
| 29/09/25 | 3.50 | 3.57 | 3.34 | 3.39 | 195,500 |
| 26/09/25 | 3.80 | 3.80 | 3.602 | 3.68 | 63,900 |
| 25/09/25 | 3.85 | 3.90 | 3.66 | 3.77 | 109,000 |
| 24/09/25 | 3.53 | 3.86 | 3.53 | 3.855 | 143,600 |
| 23/09/25 | 3.71 | 3.71 | 3.51 | 3.60 | 94,800 |
| 22/09/25 | 3.60 | 3.782 | 3.545 | 3.63 | 227,800 |
| 19/09/25 | 3.612 | 3.72 | 3.49 | 3.50 | 122,900 |
| 18/09/25 | 3.57 | 3.62 | 3.431 | 3.61 | 133,000 |
| 17/09/25 | 3.50 | 3.62 | 3.37 | 3.57 | 253,000 |
|
|
||||
|
|
||||
|
|